Clinical Study
Treatment of Uterine Myoma with 2.5 or 5 mg Mifepristone Daily during 3 Months with 9 Months Posttreatment Followup: Randomized Clinical Trial
Table 5
Changes in endometrial thickness (mm) by treatment groups and evaluation periods.
| Evaluation at | Group | | Mean ± S.D. | 95% CI for mean | Changes (%) | |
| Before treatment | 2.5 mg | 110 | 6.8 ± 1.9 | 6.5–7.3 |
— | 1.000 | 5 mg | 110 | 6.8 ± 1.9 | 6.4–7.3 | 3-month treatment | 2.5 mg | 102 | 8.9 ± 3.7 | 7.9–9.4 | 30.9 ↑ | .846 | 5 mg | 106 | 9.0 ± 3.7 | 8.4–10.0 | 32.3 ↑ | 3-month followup | 2.5 mg | 98 | 7.7 ± 2.3 | 7.1–8.2 | 13.2 ↑ | .758 | 5 mg | 104 | 7.8 ± 2.3 | 7.3–8.3 | 14.7 ↑ | 6-month followup | 2.5 mg | 93 | 7.7 ± 2.4 | 7.2–8.3 | 13.2 ↑ | .594 | 5 mg | 103 | 7.9 ± 2.8 | 7.3–8.3 | 16.2 ↑ | 9-month followup | 2.5 mg | 90 | 7.5 ± 1.9 | 7.1–7.9 | 10.3 ↑ | 1.000 | 5 mg | 100 | 7.5 ± 2.5 | 7.0–8.0 | 10.3 ↑ |
|
|
-test (ANOVA); CI: confidence interval, SD: standard deviation.
|